CommercialAdministrativeLow impact
06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)
Independence Blue Cross·Cardiology, Genetics, Pathology·Medical Policy
We identified it
Jun 19, 2026
Summary
This is a routine annual reissue of Independence Administrators' genetic testing policy for congenital Long QT Syndrome with no substantive changes to coverage criteria or billing codes. The policy clarifies that it applies only to members whose groups have NOT enrolled in the UM vendor program; groups with UM vendor enrollment should refer to the eviCore Lab Management Program instead.
Action Required
No immediate action required. This is a routine annual policy reissue with no substantive changes. Billing and clinical staff should verify that their current processes align with the disclaimer language clarification: confirm that your group's enrollment status with Independence Administrators' UM vendor program is understood, as this policy does NOT apply to groups enrolled in the UM vendor program. If your group is enrolled in UM vendor, refer claims to the eviCore Lab Management Program policy instead. Ensure genetic testing orders for LQTS continue to meet the five documented medical necessity criteria (prolonged QTc >440 msec, family history of mutation, family history of clinical LQTS, Schwartz criteria, or syncope/palpitations with family history of sudden cardiac death) and are ordered by a cardiologist.